Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients

germline genetic testing for patients with PCa did not cause appreciable psychological harm to the tested patients. Furthermore, patients with positive results had a high uptake of clinician-recommended management strategies. Of note, there were inconsistencies in the understanding of VUS results, with some clinicians making recommendations not warranted by personal/family history; conversely, some patients pursued management strategies not recommended by their clinicians. This suggests that educational efforts are needed in the communication of germline genetic testing results and clinical recommendations to patients.

Authors

Institutions

Publication Details

Journal
Prostate Cancer and Prostatic Diseases
Published
2025-09-22
DOI
https://doi.org/10.1038/s41391-025-01013-3
Citations
1
Primary Topic
BRCA gene mutations in cancer
Type
article
Field-Weighted Citation Impact
1.82

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients

Laurence Belkoff, Edward D. Esplin, Joseph Veys, Richard Bevan-Thomas et al.
1 citations
Prostate Cancer and Prostatic Diseases
BRCA gene mutations in cancer
1.82
article

Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients

Laurence Belkoff, Edward D. Esplin, Joseph Veys, Richard Bevan-Thomas, Christopher Pieczonka, Paul Dato, Sarah M. Nielsen, Mary Kay Hardwick, Aaron D. Berger, David Cahn, Brandie Heald, Brianna Bucknor, Kathryn E. Hatchell, David R. Wise, Kerry Aradhya, Alexander Engelman, Sean Heron, Neal D. Shore, David S. Morris, Brian C. Mazzarella, Mukaram Gazi, Robert L. Nussbaum
article en
1 citations

Abstract

germline genetic testing for patients with PCa did not cause appreciable psychological harm to the tested patients. Furthermore, patients with positive results had a high uptake of clinician-recommended management strategies. Of note, there were inconsistencies in the understanding of VUS results, with some clinicians making recommendations not warranted by personal/family history; conversely, some patients pursued management strategies not recommended by their clinicians. This suggests that educational efforts are needed in the communication of germline genetic testing results and clinical recommendations to patients.

Prostate Cancer and Prostatic Diseases
University of California, San Francisco (US), SUNY Upstate Medical University (US), Genesis HealthCare (US), NYU Langone Health (US), Georgia Urology (US), Urology Associates (US), Genesis Healthcare (US), Syracuse VA Medical Center (US), AdventHealth Tampa (US), Nashville Oncology Associates (US), Invitae (United States) (US), Advanced Dermatology (US), Carolina Urologic Research Center (US), DGA Partners (US)
Invitae
Openalex Percentile: Top 12%
BRCA gene mutations in cancer
1.82
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.